Publicação
The biggest healthcare acquisition of 2022: Johnson & Johnson acquires abiomed inc
| Resumo: | This thesis investigates the rationale, financial elements, and market effects of Johnson & Johnson's acquisition of Abiomed Inc. in 2022. The acquisition was facilitated in large part by Abiomed's innovative Impella heart pump technology, which fit in well with Johnson & Johnson's plan to control the rapidly expanding cardiovascular device market. The $16.6 billion deal, including the use of contingent value rights to align shareholder interests, is examined in the report. It also looks at post-acquisition technology integration and regulatory issues, highlighting the wider implications for future advancements in healthcare and competitive market positioning. |
|---|---|
| Autores principais: | Giribono, Marco |
| Assunto: | Mergers & acquisitions Contingent value right Covid-19 pandemic Corporate strategy Cardiovascular health Healthcare innovation Financial analysis Technological integration |
| Ano: | 2024 |
| País: | Portugal |
| Tipo de documento: | dissertação de mestrado |
| Tipo de acesso: | acesso aberto |
| Instituição associada: | Universidade Nova de Lisboa |
| Idioma: | inglês |
| Origem: | Repositório Institucional da UNL |
| Resumo: | This thesis investigates the rationale, financial elements, and market effects of Johnson & Johnson's acquisition of Abiomed Inc. in 2022. The acquisition was facilitated in large part by Abiomed's innovative Impella heart pump technology, which fit in well with Johnson & Johnson's plan to control the rapidly expanding cardiovascular device market. The $16.6 billion deal, including the use of contingent value rights to align shareholder interests, is examined in the report. It also looks at post-acquisition technology integration and regulatory issues, highlighting the wider implications for future advancements in healthcare and competitive market positioning. |
|---|